Content
Why Intellia Therapeutics, Inc. Outpaced The Stock Market
Article By:
Zacks Investment Research
Read
Sunday, May 5, 2024 11:37 AM EDT
Investors will be eagerly watching for the performance of Intellia Therapeutics, Inc. in its upcoming earnings disclosure.
In this article: NTLA
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
Article By:
Lorimer Wilson
Read
Sunday, May 5, 2024 12:02 AM EDT
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD.
Market Fluctuates Amid Fed Decision And Mixed Corporate Earnings And Economic Signals
Article By:
The Private Banker
Read
Thursday, May 2, 2024 6:30 AM EDT
The U.S. stock markets exhibited mixed responses on Wednesday as investors navigated through a complex landscape of disappointing corporate earnings and a slew of economic data.
Pfizer Q1 Earnings And Revenues Beat Estimates
Article By:
Zacks Investment Research
Read
Wednesday, May 1, 2024 9:40 AM EDT
PFE came out with quarterly earnings of $0.82 per share, beating the our eimate of $0.56 per share. This compares to earnings of $1.23 per share a year ago.
TG Therapeutics Stock Just Rallied 30%: What Happened?
Article By:
Wajeeh Khan
Read
Wednesday, May 1, 2024 9:39 AM EDT
TG Therapeutics Inc (NASDAQ: TGTX) is up 30% on Wednesday even though it reported a wider-than-expected per-share loss for its fiscal first quarter.
In this article: TGTX
Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates
Article By:
Zacks Investment Research
Read
Sunday, April 28, 2024 4:00 PM EDT
The first-quarter 2024 earnings season picked up pace this week, with Merck, Sanofi, Novartis, and AstraZeneca announcing their first-quarter results. Three of the four companies beat estimates for both earnings and sales in the first quarter.
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
Article By:
Lorimer Wilson
Read
Tuesday, April 23, 2024 12:57 PM EDT
A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and MTD, and their areas of focus.
Sweet Nektar?
Article By:
Tim Knight
Read
Monday, April 22, 2024 1:40 PM EDT
NKTR has had a terrible time of it for years, but maybe it’s finally ready to turn around.
In this article: NKTR
The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD
Article By:
Lorimer Wilson
Read
Monday, April 15, 2024 6:45 AM EDT
The pharmaceutical industry is embracing AI to streamline drug discovery and researching the use of psychedelic compound-based ingredients for the treatment of, as yet, untreatable diseases.
Alvotech's Share Price At A Critical Juncture
Article By:
Hallsteinn Arnarson
Read
Saturday, April 13, 2024 7:50 PM EDT
Insights into the largest company, market-cap-wise, on the Iceland market.
Viking Therapeutics: Strong Results In Obesity
Article By:
MoneyShow.com
Read
Saturday, April 13, 2024 5:17 PM EDT
With a potential best in class drug for oral and injectable use, Viking Therapeutics has to be on many Big Pharma/Bio acquisition wish lists, as the company represents a very scarce asset in the $100 billion market for weight loss drugs.
MicroMarvel - Atossa Therapeutics
Article By:
Jim Van Meerten
Read
Saturday, April 6, 2024 7:49 PM EDT
Atossa Therapeutics, a biopharmaceutical company focused on developing medicines in oncology, has a lead program in Phase II clinical trials for breast cancer, and 100% technical buy signals
In this article: ATOS
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
Article By:
ChinaBio® Today
Read
Saturday, April 6, 2024 1:20 PM EDT
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates for solid tumors.